WallStreetZenWallStreetZen

NASDAQ: HRMY
Harmony Biosciences Holdings Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Harmony Biosciences Holdings earnings were $152.7M for the trailing 12 months ending Mar 31, 2025, with 13.6% growth year over year. The latest HRMY earnings report on Mar 31, 2025 announced Q1 2025 earnings of $45.6M, down 7.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, HRMY reported annual earnings of $145.5M, with 12.9% growth.

HRMY past earnings growth

How has HRMY's earnings growth performed historically?

Company
13.62%
Industry
11.53%
Market
34%
HRMY's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
HRMY's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
HRMY's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

HRMY earnings history

Current Revenue
$744.9M
Current Earnings
$152.7M
Current Profit Margin
20.5%

HRMY Return on Equity

Current Company
24.3%
Current Industry
-60.2%
Current Market
31.5%
HRMY's Return on Equity (24.3%)... subscribe to Premium to read more.
High Return on Equity Performance

HRMY undefined

Current Company
15.9%
Current Industry
-2.5%
HRMY is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when HRMY announces earnings.

HRMY undefined

Current Company
24.31%
Current Industry
5.8%
HRMY has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

HRMY vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
HRMY$237.95M$152.72M+69.96%$2.67
GLPGN/AN/AN/AN/A
BLTE-$35.67M-$36.14MN/A-$1.18
IRON-$114.00M-$116.49MN/A-$3.92
FOLD$53.63M-$29.37MN/A-$0.09
View Top Biotech Stocks

Harmony Biosciences Holdings Earnings Reports & History FAQ

What were Harmony Biosciences Holdings's earnings last quarter?

On HRMY's earnings call on Invalid Date, Harmony Biosciences Holdings (NASDAQ: HRMY) reported Q1 2025 earnings per share (EPS) of $0.79, up 16.18% year over year. Total HRMY earnings for the quarter were $45.56 million. In the same quarter last year, Harmony Biosciences Holdings's earnings per share (EPS) was $0.68.

If you're new to stock investing, here's how to buy Harmony Biosciences Holdings stock.

Is Harmony Biosciences Holdings profitable or losing money?

As of the last Harmony Biosciences Holdings earnings report, Harmony Biosciences Holdings is currently profitable. Harmony Biosciences Holdings's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $152.72 million, a 10.91% increase year over year.

What was HRMY's earnings growth in the past year?

As of Harmony Biosciences Holdings's earnings date in Invalid Date, Harmony Biosciences Holdings's earnings has grown 13.62% year over year. This is 2.09 percentage points higher than the US Biotechnology industry earnings growth rate of 11.53%. HRMY earnings in the past year totalled $152.72 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.